Contact
NanoBone®

POWER TO REMODEL RAPIDLY

Perfect partner for remodelling bone defects rapidly

Reliable and convenient, NanoBone is a next generation, fully synthetic bone graft substitute.
Consisting of nanostructured hydroxyapatite (HA) embedded in a silica gel matrix – suspended in a hydrogel/polymer silica carrier – it provides the fullest support for bone regeneration at every stage of the healing process.

  • Comparable healing rate to autograft without the costs and complications of harvesting1
  • Rapid absorption and reliable bone fusion1
  • Proven osteoinductive properties2
  • Early osteogenesis – silica matrix exchanged for autologous proteins within 10 days3
  • Patented nanostructure and optimised composition4
  • Preloaded, versatile and ready to use4

Patented nanostructure and optimised composition

Unlike traditional synthetic HA scaffolds, the HA in NanoBone is precipitated and unsintered to preserve its highly porous and permeable nanoarchitecture and degradation properties. When combined with the high porosity silica gel matrix, NanoBone offers distinct design properties for successful bone healing:5

• Nanostructure of HA platelets is identical in morphology to HA in bone6,7,8
• Nanostructure increases autologous protein enrichment3,9
• Proven osteoinductive properties2

Nanostructure of HA platelets is identical in morphology to HA in bone

NanoBone is precipitated to achieve a HA morphology that mimics the HA in natural bone and ensures that complete natural bone remodelling takes place. Traditional sintered HA consists of larger connected crystals which lower porosity and its ability to degrade.10,11

HA diffraction patterns8

Nanostructure increases autologous protein enrichment

High inner surface area is key to biological efficiency. Increasing the interaction between NanoBone and serum increases autologous
protein enrichment and formation of an extracellular matrix to start bone healing.3,9,11

Specific surface area9,11,12

Proven osteoinductive properties

Exchange of the silica gel for autologous proteins, in combination with nanostructured HA, provides a compound very similar to that of skeletal bone and promotes bone remodelling.2,11

Histomorphometric findings in subcutaneous tissue2

Define success on a different scale

In clinical studies, NanoBone achieved rapid, reliable fusion with complications and healing rates at least comparable with autograft.1

  • Rapid and reliable fusion
  • No need for biological bone graft – but can be easily added
  • No foreign body reaction

NanoBone ALIF study14

 

NanoBone PLIF study15

 

NanoBone benign bone tumour study16

98 patients with benign bone tumours
Implantation sites included:

  • proximal humerus
  • distal radius
  • femur
  • tibia
  • hand
  • foot

No post-operative infections or fracture with long-term follow-up

– illustrating stages of remodelling and healing

NanoBone® products
NanoBone SBX Putty

High extrusion volume
for placement into larger
open wounds

Available as 1.0 ml, 2.5 ml, 5.0 ml and 10.0 ml

NanoBone QD

Slender profile for placement
into deep cavities and minimally
invasive procedures

Available as 1.0 ml, 2.5 ml, 5.0 ml and 10.0 ml

Library

Listed below are 4 of the most relevant articles for this product but there is much more unrivalled evidence to explore on our Library page.

Explore Library

References and regulatory statements

Biocomposites GmbH (former ARTOSS GmbH)

1. Kienast B et al. (2016). Nanostrukturiertes synthetisches Knochenersatzmaterial zur Behandlung von Knochendefekten, Trauma und
Berufskrankheit, 4(18), 308-18. 2. Götz W et al. (2010). A preliminary study in osteoinduction by a nano-crystalline hydroxyapatite in the mini pig. Folia histochemica et cytobiologica, 48(4), 589-596. 3. Xu W (2011). Evaluation of injectable silica-embedded nanohydroxyapatite bone substitute in a rat tibia defect model. Int J Nanomedicine, 6, 1543-52. 4. NanoBone® Summary of product characteristics. 5. Meier J et al. (2008). Application of the synthetic nanostructured bone grafting material NanoBone® in sinus floor elevation, Implantologie, 16, 301-14. 6. Fratzl, P., et al., (1991). Nucleation and Growth of Mineral Crystals in Bone Studied by Small-Angle-X-Ray Scattering, Calcif Tissue Int., 48, 407-413. 7. Weiner, S., et al., (1986). Disaggregation of Bone Into Crystals, Calcif Tissue Int., 39, 365-375. 8. Scherrer P., (1918). Bestimmung der Grösse und der inneren Struktur von Kolloidteilchen mittels Röntgenstrahlen, Nachrichten von der Gesellschaft der Wissenschaften zu Göttingen, Mathematisch-Physikalische Klasse, 98-100. 9. Kirchhoff M et al. (2011). Lateral augmentation of the mandible in minipigs with a synthetic nanostructured hydroxyapatite block. Journal of biomedical materials research. Part B, Applied biomaterials, 96(2), 342–350. 10. Götz W et al. (2008). Immunohistochemical characterization of nanocrystalline hydroxyapatite silica gel (NanoBone) osteogenesis: a study on biopsies from human jaws. Clinical oral implants research, 19(10), 1016–1026. 11. Gerber T et al. (2012). Nanostructured bone grafting substitutes – A pathway to osteoinductivity. In Key Engineering Materials, 493, 147-152. 12. Data on file, External testing: Specific surface area, 2010. 13. Abshagen K et al. (2009). In vivo analysis of biocompatibility and vascularization of the synthetic bone grafting substitute NanoBone®. Journal of Biomedical Materials Research Part A: An Official Journal of The Society for Biomaterials, The Japanese Society for Biomaterials, and The Australian Society for Biomaterials and the Korean Society for Biomaterials, 91(2), 557-566. 14. Rickert M et al. (2019). Clinical Outcome After Anterior Lumbar Interbody Fusion with a New Osteoinductive Bone Substitute Material: A Randomized Clinical Pilot Study. Clinical spine surgery, 32(7), E319–E325. 15. Hebecker R et al. (2008, June 1). A new nanostructured bone substitute for use in neurosurgery – results of a prospective study in lumbar fusion and further applications. 59th Annual Meeting of the German Society of Neurosurgery (DGNC) 3rd Joint Meeting with the Italian Neurosurgical Society (SINch). 16. Rosenthal H. (2022). Evaluating a Nanocrystalline Hydroxyapatite Bone Graft Substitute for the Treatment of Benign Bone Tumors. The Internet Journal of Orthopedic Surgery, 30(1).

©2024, Biocomposites is a trademark/registered trademark of Biocomposites Ltd. NanoBone is a trademark/registered trademark of Biocomposites GmbH. All rights reserved.
No unauthorised copying, reproduction, distributing or republication is allowed unless prior written permission is granted by the owner, Biocomposites Ltd.
Patents granted: EP 1 624 904 B1, US 8,715,744 B2, JP4764821B2, 284158, CA2537620C, RU2354408C2, ZL200480020915.3, DE 50 2004 002 554.4, ES2280969T3, AU 2004241740 B2, HK1080766A1, EP 3 600 464 B1, US 11,324,859 B2, JP7118132B2, CN110650754B, DE 50 2018 009 567.7, ES2917406T3, MX2019011659A, RU2768695C2, 386769, AU2018246310A1, BR112019020029A2, CA3058253A1

MA0443R2